← Back to headlines
Corcept Therapeutics Faces Setback in Korlym Patent Dispute with Teva
Corcept Therapeutics' stock declined after an appeals court ruled in favor of Teva Pharmaceuticals in a patent dispute concerning Corcept's drug Korlym.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
